Advertisement


Mansoor Raza Mirza, MD, on Endometrial Cancer: Palbociclib Plus Letrozole in ER-Positive Disease

ESMO Virtual Congress 2020

Advertisement

Mansoor Raza Mirza, MD, of Copenhagen University Hospital, discusses phase II study results that showed the combination of palbociclib and letrozole, compared with placebo plus letrozole, improved progression-free survival in patients with estrogen receptor–positive advanced or recurrent endometrial cancer (Abstract LBA28).



Related Videos

Breast Cancer
Immunotherapy

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Treatment of Physician’s Choice

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses results from the phase III ASCENT trial, which showed the antibody-drug conjugate sacituzum...

Skin Cancer
Immunotherapy

Jeffrey S. Weber, MD, PhD, on Melanoma: Adjuvant Nivolumab vs Ipilimumab

Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-yea...

Breast Cancer

Erica L. Mayer, MD, MPH, on Early Breast Cancer: Palbociclib With Endocrine Therapy vs Endocrine Therapy Alone

Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, discusses an initial analysis of phase III findings from the PALLAS trial, which suggested the benefits observed in ...

Skin Cancer
Immunotherapy

Alexander M. Eggermont, MD, PhD, on Melanoma: Pembrolizumab vs Placebo After Complete Resection

Alexander M. Eggermont, MD, PhD, of the Princess Maxima Center for Pediatric Oncology, discusses final results of the phase III EORTC 1325-MG/Keynote 054 trial, which confirm...

Breast Cancer
Symptom Management

Monika K. Krzyzanowska, MD, MPH, on Early-Stage Breast Cancer: Ambulatory Toxicity Management in the AToM Study

Monika K. Krzyzanowska, MD, MPH, of the Princess Margaret University Health Network, discusses study findings on remote proactive telephone-based toxicity management for patients w...

Advertisement

Advertisement



Advertisement